Perspective | Published:

Digital phenotyping approaches and mobile devices enhance CNS biopharmaceutical research and development

Neuropsychopharmacologyvolume 43pages25042505 (2018) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Additional information

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.

    Torous J, Chan SR, Yee-Marie Tan S, Behrens J, Mathew I, Conrad EJ, et al. Patient smartphone ownership and interest in mobile apps to monitor symptoms of mental health conditions: a survey in four geographically distinct psychiatric clinics. JMIR Ment Health. 2014;1:e5.

  2. 2.

    Torous J, Friedman R, Keshavan M. Smartphone ownership and interest in mobile applications to monitor symptoms of mental health conditions. JMIR Mhealth Uhealth. 2014;2:e2.

  3. 3.

    Gold M, Amatniek J, Carrillo MC, Cedarbaum JM, Hendrix JA, Miller BB, et al. Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer’s disease clinical trials. Alzheimers Dement. 2018;4:234–42.

  4. 4.

    Espay AJ, Bonato P, Nahab FB, Maetzler W, Dean JM, Klucken J, et al. Technology in Parkinson’s disease: challenges and opportunities. Mov Disord. 2016;31:1272–82.

  5. 5.

    Onnela JP, Rauch SL. Harnessing smartphone-based digital phenotyping to enhance behavioral and mental health. Neuropsychopharmacology . 2016;41:1691–6.

  6. 6.

    Torous J, Staples P, Onnela JP. Realizing the potential of mobile mental health: new methods for new data in psychiatry. Curr Psychiatry Rep. 2015;17:602.

  7. 7.

    The Boston Globe. Every step you take. Accessed 7 July 2018.

  8. 8.

    Arroyo-Gallego T, Ledesma-Carbayo MJ, Sanchez-Ferro A, Butterworth I, Mendoza CS, Matarazzo M, et al. Detection of motor impairment in Parkinson’s Disease via mobile touchscreen typing. IEEE Trans Biomed Eng. 2017;64:1994–2002.

  9. 9.

    Dagum P.Digital biomarkers of cognitive function. npj Digital Med. 2018;1:10

  10. 10.

    Staples P, Torous J, Barnett I, Carlson K, Sandoval L, Keshavan M, et al. A comparison of passive and active estimates of sleep in a cohort with schizophrenia. NPJ Schizophr. 2017;3:37.

  11. 11.

    Tal A, Torous J. The digital mental health revolution: opportunities and risks. Psychiatr Rehabil J. 2017;40:263–5.

  12. 12.

    Torous J, Staples P, Barnett I, Sandoval LR, Keshavan M, Onnela JP. Characterizing the clinical relevance of digital phenotyping data quality with applications to a cohort with schizophrenia. npj Digit Med. 2018;1:15.

  13. 13.

    Hyman SE. Psychiatric drug development: diagnosing a crisis. Cerebrum. 2013 Apr 2:2013:5.

  14. 14.

    Torous J, Onnela JP, Keshavan M. New dimensions and new tools to realize the potential of RDoC: digital phenotyping via smartphones and connected devices. Transl Psychiatry. 2017;7:e1053.

  15. 15.

    Clementz BA, Sweeney JA, Hamm JP, Ivleva EI, Ethridge LE, Pearlson GD, et al. Identification of distinct psychosis biotypes using brain-based biomarkers. Am J Psychiatry. 2016;173:373–84.

  16. 16.

    Drysdale AT, Grosenick L, Downar J, Dunlop K, Mansouri F, Meng Y, et al. Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nat Med. 2017;23:28–38.

  17. 17.

    Williams LM. Precision psychiatry: a neural circuit taxonomy for depression and anxiety. Lancet Psychiatry. 2016;3:472–80.

  18. 18.

    Cambridge Cognition. Cognition Kit wearable technology demonstrates high compliance among patients with major depressive disorder (MDD). Accessed 7 July 2018.

  19. 19.

    Smith DG, Saljooqi K, Alvarez-Horine S, Dagum P, Madrid A. Exploring novel behavioral tasks and digital phenotyping technologies as adjuncts to a clinical trial of BTRX-246040. Accessed 7 July 2018.

  20. 20.

    Barnett I, Torous J, Staples P, Sandoval L, Keshavan M, Onnela JP. Relapse prediction in schizophrenia through digital phenotyping: a pilot study. Neuropsychopharmacology. 2018;43:1660–6.

Download references

Author information


  1. Department of Clinical Research, Alkermes Incorporated, Waltham, MA, 02451, USA

    • Daniel G. Smith


  1. Search for Daniel G. Smith in:

Competing interests

The author declares no competing interests.

Corresponding author

Correspondence to Daniel G. Smith.

About this article

Publication history